These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38703896)

  • 21. Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction.
    Chang HY; Su YW; Feng AN; Fong MC; Huang KC; Chong E; Chen KC; Yin WH
    ESC Heart Fail; 2020 Apr; 7(2):604-615. PubMed ID: 31995274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Mar; 352():i1450. PubMed ID: 27029547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guideline-recommended medications: variation across Medicare Advantage plans and associated mortality.
    Selim AJ; Fincke BG; Rogers WH; Qian S; Selim BJ; Kazis LE
    J Manag Care Pharm; 2013 Mar; 19(2):132-8. PubMed ID: 23461429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
    JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.
    Bennett WL; Maruthur NM; Singh S; Segal JB; Wilson LM; Chatterjee R; Marinopoulos SS; Puhan MA; Ranasinghe P; Block L; Nicholson WK; Hutfless S; Bass EB; Bolen S
    Ann Intern Med; 2011 May; 154(9):602-13. PubMed ID: 21403054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing Guideline-Directed Medication Therapy for Heart Failure in End-Stage Renal Disease.
    Cutshall BT; Duhart BT; Saikumar J; Samarin M; Hutchison L; Hudson JQ
    Am J Med Sci; 2018 Mar; 355(3):247-251. PubMed ID: 29549927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
    Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
    Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure.
    Tran RH; Aldemerdash A; Chang P; Sueta CA; Kaufman B; Asafu-Adjei J; Vardeny O; Daubert E; Alburikan KA; Kucharska-Newton AM; Stearns SC; Rodgers JE
    Pharmacotherapy; 2018 Apr; 38(4):406-416. PubMed ID: 29423950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetologia; 2015 Jan; 58(1):50-8. PubMed ID: 25205223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database.
    MacDonald MR; Eurich DT; Majumdar SR; Lewsey JD; Bhagra S; Jhund PS; Petrie MC; McMurray JJ; Petrie JR; McAlister FA
    Diabetes Care; 2010 Jun; 33(6):1213-8. PubMed ID: 20299488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction.
    Kocabaş U; Ergin I; Kıvrak T; Yılmaz Öztekin GM; Tanık VO; Özdemir İ; Avcı Demir F; Doğduş M; Şen T; Altınsoy M; Üstündağ S; Urgun ÖD; Sinan ÜY; Uygur B; Yeni M; Özçalık E
    ESC Heart Fail; 2023 Dec; 10(6):3677-3689. PubMed ID: 37804042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
    Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
    ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.
    Maru S; Koch GG; Stender M; Clark D; Gibowski L; Petri H; White AD; Simpson RJ
    Diabetes Care; 2005 Jan; 28(1):20-6. PubMed ID: 15616228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.